【摘要】 目的 探讨前列腺癌(PCa)手术切除标本中微小核糖核酸-218(miR-218)、组蛋白伴侣抗沉默功能蛋白1B(ASF1B)表达与病理进展的关系及对生存率的影响。方法 选取新乡医学院第一附属医院2019年1月至2021年5月收治的113例PCa患者，获取所有患者的手术切除标本。比较手术切除标本中癌组织与癌旁组织miR-218、ASF1B表达情况，绘制受试者工作特征(ROC)曲线，获取miR-218、ASF1B在癌组织与癌旁组织中的最佳截断值，比较不同病理情况患者癌组织的miR-218、ASF1B表达情况，Spearman法分析癌组织miR-218、ASF1B与病理进展的关系，并随访3 a,统计3 a生存率，对比不同miR-218、ASF1B表达患者3 a生存率。结果 癌组织的miR-218 mRNA表达低于癌旁组织，ASF1B mRNA表达高于癌旁组织(P<0.05);ROC分析显示，miR-218、ASF1B在癌组织与癌旁组织中的最佳截断值分别为0.59、2.61,曲线下面积(AUC)分别为0.769(95%CI:0.709～0.823)、0.820(95%CI:0.764～0.868);临床分期为Ⅲ～Ⅳ期、肿瘤直径≥3 cm、发生淋巴结转移、发生微血管侵犯、分化程度为未-低分化患者癌组织的miR-218 mRNA表达低于临床分期为Ⅰ～Ⅱ期、肿瘤直径<3 cm、未发生淋巴结转移、未发生微血管侵犯、分化程度为中-高分化患者，ASF1B mRNA相对表达量趋势与miR-218 mRNA相反(P<0.05);miR-218 mRNA表达量与PCa患者的临床分期高低、肿瘤直径大小、是否发生淋巴结转移、是否发生微血管侵犯呈负相关，与分化程度呈正相关，ASF1B与病理特征相关性与miR-218相反(P<0.05);Kaplan-Meier曲线分析，miR-218 mRNA低表达的PCa患者3 a生存率低于高表达患者，ASF1B mRNA高表达的3 a生存率低于低表达的(P<0.05)。结论 PCa组织中miR-218 mRNA相对表达量下降，ASF1B mRNA相对表达量升高，二者表达与临床分期、肿瘤直径、淋巴结转移、微血管侵犯、分化程度及3 a生存率相关，可作为临床评估PCa病理进展、预测3 a生存率的相关标志物，并指导临床工作。更多还原

【Abstract】 Objective To investigate the relationship between the expression of microRNAs 218(miR-218) and histone chaperone anti-silence functional 1B(ASF1B) and the pathological progression and the effect on the survival rate in prostate cancer(PCa) surgically resected specimens.Methods A total of 113 PCa patients admitted to the First Affiliated Hospital of Xinxiang Medical University from January 2019 to May 2021 were selected, and surgical excision specimens of all patients were obtained. The expression of miR-218 and ASF1B in PCa cancer tissues and adjacent tissues in surgically resected specimens was compared, and the optimal cut-off values of miR-218 and ASF1B in cancer tissues and adjacent tissues were obtained by drawing receiver operating characteristic(ROC) curve, and the expression of miR-218 and ASF1B in cancer tissues with different pathological conditions were compared. The relationship between miR-218 and ASF1B in cancer tissue and pathological progression was analyzed by Spearman method, and the 3-year follow-up was conducted to analyze the 3-year survival rate, and the 3-year survival rate of patients with different expressions of miR-218 and ASF1B was compared.Results The relative expression level of miR-218 mRNA in cancer tissues was lower than that in paracancer tissues, and the relative expression level of ASF1B mRNA was higher than that in paracancer tissues(P<0.05). ROC curve showed that the optimal cut-off values of miR-218 and ASF1B in cancer tissues and adjacent tissues were 0.59 and 2.61, respectively, and the area under the curve(AUC) were 0.769(95% CI: 0.709-0.823) and 0.820(95% CI: 0.764-0.868), respectively. The expression of miR-218 mRNA in cancer tissues with clinical stage Ⅲ-Ⅳ, tumor diameter ≥3 cm, lymph node metastasis, microvascular invasion, and undifferentiated cancer was lower than that of patients with stage Ⅰ-Ⅱ and tumor diameter < 3 cm, no lymph node metastasis, no microvascular invasion, medium to highly differentiated patients. The relative expression level of ASF1B mRNA was opposite to that of miR-218 mRNA, the differences were statistically significant(P<0.05). The miR-218 mRNA was negatively correlated with clinical stage, tumor diameter, lymph node metastasis, and microvascular invasion in PCa patients, and positively correlated with differentiation degree. The correlation between ASF1B mRNA and pathological features was opposite to that of miR-218 mRNA(P<0.05). Kaplan-Meier curve analysis showed that the 3-year survival rate of PCa patients with low expression of miR-218 was lower than that of PCa patients with high expression of miR-218 mRNA. The 3-year survival rate with high expression of ASF1B mRNA was lower than low expression(P<0.05).Conclusion The relative expression of miR-218 mRNA decreased in PCa tissues, while the relative expression of ASF1B mRNA increased. The expression of miR-218 mRNA was correlated with clinical stage, tumor diameter, lymph node metastasis, microvascular invasion, differentiation degree and 3-year survival rate, and could be used as relevant markers for clinical evaluation of PCa pathological progress and prediction of 3-year survival rate, and to guide clinical work.更多还原